AMY PUCKETT: Open Payments
NPI 1225362932 · EASTMAN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 30 payments from 13 companies in 2025. Trend: 2023 $574 · 2024 $476 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $99 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $92 |
| AstraZeneca Pharmaceuticals LP | 4 | $64 |
| Lundbeck LLC | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Lilly USA, LLC | 2 | $40 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: REXULTI, Ozempic, Kerendia, NEXLETOL, MOUNJARO, BREZTRI, COBENFY, INGREZZA.
Industry payments across GA — which companies pay providers there.
